Adcock Ingram Limited

Adcock Ingram Limited, incorporated on April 3, 2007, is a public unlisted company based in Bengaluru, Karnataka, India. Its Corporate Identification Number (CIN) is U24232KA2007PLC042361. The company is primarily engaged in the manufacturing of chemicals and chemical products, focusing on finished pharmaceutical formulations such as tablets, capsules, syrups, and injections.

As of the latest available data, Adcock Ingram Limited has an authorized capital of ₹400 million and a paid-up capital of ₹380.5 million. The company's registered office is located at Plot No. 49 D, Bommasandra Industrial Area, Anekal Taluk, Bengaluru, Karnataka, 560099, India.

In August 2023, Chandra Mohan was appointed as the Chief Financial Officer (CFO), bringing over two years of experience with the company.

Adcock Ingram Limited operates a manufacturing facility situated in the Bommasandra Industrial Area of Bengaluru, Karnataka. This plant specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The facility is strategically located to serve both domestic and international markets, ensuring efficient distribution and compliance with regulatory standards.

The leadership team at Adcock Ingram Limited is headed by Chandra Mohan, who assumed the role of Chief Financial Officer (CFO) in August 2023. His appointment reflects the company's commitment to strengthening its financial management and strategic direction. The board of directors includes Pravin Vaidyanathan Iyer, Alok Sharma, Pankaj Garg, Yasuhiro Nakagiri, and others, each bringing diverse expertise to the company's governance.

Adcock Ingram Limited's export portfolio, valued at $98.8 million USD over 4,011 shipments, includes 13 products across seven therapeutic categories. Notably, the company holds the number one market position in Paracetamol and Caffeine, with market shares of 7.8% and 20.7%, respectively. These products are essential in the analgesics and antipyretics category, which constitutes 69.2% of their export value. The company's strong presence in regulated markets underscores its adherence to international quality standards and regulatory requirements.

Adcock Ingram Limited's strategic focus on emerging markets is evident through its significant export activities in regions such as Africa, Latin America, and Southeast Asia. The company's adherence to WHO prequalification standards has facilitated access to these markets, enabling it to offer a range of pharmaceutical products that meet international quality benchmarks. This approach not only broadens the company's market reach but also contributes to improving healthcare access in these regions.

Adcock Ingram Limited's export strategy demonstrates a diversified approach, with a significant concentration in the analgesics and antipyretics category (69.2%) and respiratory products (22.8%). This focus indicates a strategic direction aimed at addressing prevalent health concerns globally. However, the high concentration in a few product categories suggests potential risks related to market fluctuations and regulatory changes. Diversifying the product portfolio and exploring new therapeutic areas could mitigate these risks and enhance the company's resilience in the global market.

As of the latest available data, Adcock Ingram Limited has not reported any FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), or Drug Master File (DMF) filings. The company has not been subject to any FDA Form 483 observations, warning letters, or import alerts. This indicates that Adcock Ingram Limited has not pursued market access in the United States, focusing its efforts on other international markets.

Adcock Ingram Limited's commitment to quality is demonstrated by its adherence to WHO prequalification standards, facilitating access to various international markets. The company holds EU Good Manufacturing Practice (GMP) certificates, ensuring that its manufacturing processes meet the stringent requirements set by the European Directorate for the Quality of Medicines & HealthCare (EDQM). These certifications underscore the company's dedication to producing high-quality pharmaceutical products.

Adcock Ingram Limited operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds the necessary manufacturing licenses and approvals from state drug controllers, ensuring compliance with national regulations. Additionally, Adcock Ingram Limited has obtained export No Objection Certificates (NOCs), authorizing it to export pharmaceutical products to various international markets.

As of the latest available information, Adcock Ingram Limited has not been subject to any regulatory actions, including Form 483 observations, warning letters, or import alerts from regulatory bodies such as the FDA. This clean regulatory record reflects the company's commitment to maintaining high standards of quality and compliance in its operations.

In the analgesics and antipyretics category, Adcock Ingram Limited faces competition from other pharmaceutical companies with established market presence. However, the company's leadership in Paracetamol and Caffeine, with market shares of 7.8% and 20.7%, respectively, positions it favorably in the global market. The high concentration of exports in these top products indicates a strong competitive edge, though it also suggests potential vulnerabilities to market dynamics and regulatory changes.

Adcock Ingram Limited's key differentiators include its strong market position in Paracetamol and Caffeine, adherence to international quality standards such as WHO prequalification and EU GMP certifications, and a diversified export portfolio across multiple therapeutic categories. These factors contribute to the company's competitive advantage in the global pharmaceutical market.

Adcock Ingram Limited's current strategic direction focuses on the production and export of finished pharmaceutical formulations, with a significant emphasis on analgesics and antipyretics. The company's adherence to international quality standards and its strong presence in emerging markets reflect a commitment to expanding its global footprint. Future strategic initiatives may include diversifying the product portfolio, exploring new therapeutic areas, and enhancing market penetration in regulated markets to mitigate risks associated with product concentration.

Adcock Ingram Limited has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products, with a total export value of $98.8 million USD over 4,011 shipments. The company's adherence to international quality standards, as evidenced by its WHO prequalification and EU GMP certifications, indicates a high level of reliability. The concentration of exports in top products suggests a focused approach, though it also highlights the importance of diversifying the product portfolio to enhance resilience.

Importers should verify the following certifications when considering Adcock Ingram Limited as a supplier:

• WHO Prequalification: Confirms that the company's products meet international quality standards. Verification can be done through the WHO's official website.

• EU GMP Certificates: Indicate compliance with European manufacturing standards. These certificates can be verified through the European Medicines Agency (EMA).

• ISO Certifications: Demonstrate adherence to international quality management standards. Verification can be conducted through the International Organization for Standardization (ISO).

When conducting due diligence on Adcock Ingram Limited, consider the following steps:

• Verify Regulatory Compliance: Ensure the company holds valid WHO prequalification and EU GMP certificates.

• Assess Financial Stability: Review the company's financial statements and credit history to evaluate financial health.

• Evaluate Product Quality: Request samples and conduct quality assessments to confirm product standards.

• Check Export Records: Review export volumes and consistency to assess reliability.

• Monitor for Red Flags: Be alert to any discrepancies in certifications, financial records, or regulatory compliance.

By following this checklist, importers can make informed decisions and establish reliable partnerships with Adcock Ingram Limited.